Literature DB >> 15867658

Antiphospholipid inner ear syndrome.

Debbie Aviva Mouadeb1, Michael J Ruckenstein.   

Abstract

OBJECTIVE: This study was initiated to clarify the possible association between antiphospholipid antibodies, mediators of microthrombus formation, and sensorineural hearing loss (SNHL) of unknown origin in a large cohort of patients. STUDY
DESIGN: Prospective study.
METHODS: The study cohort consists of 168 adult patients (>/=18 yr) referred to the University of Pennsylvania's Division of Neurotology and Balance Center for diagnosis and treatment of progressive hearing loss with or without vertigo. A comprehensive screening panel of blood tests for autoimmune and infectious diseases was applied to all patients, including testing for anticardiolipin antibodies, anti-B2 glycoprotein, and lupus anticoagulant.
RESULTS: Forty-two patients (25%) had at least one elevated antiphospholipid antibody marker. Twenty patients had two or more positive test results. Of the 42 patients, 64% (n = 27) met the diagnostic criteria for Meniere disease, and the remainder were diagnosed with idiopathic SNHL. Within this group of patients, 24 patients (57%) had unilateral hearing loss, and 18 (44%) had bilateral hearing loss.
CONCLUSIONS: These data support the hypothesis that antiphospholipid antibodies are involved in the pathogenesis of some forms of inner ear dysfunction, presumably by causing microthrombus formation in the labyrinthine vasculature. Basic science studies are required to better understand the mechanisms by which antiphospholipid antibodies mediate inner ear dysfunction. Clinical studies to evaluate the efficacy of anticoagulation in this group of patients are also required.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867658     DOI: 10.1097/01.MLG.0000158666.15447.37

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  14 in total

1.  Meniere's disease: rare or underdiagnosed among Africans.

Authors:  T S Ibekwe; G T A Ijaduola
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-07-04       Impact factor: 2.503

2.  Vascular Pathophysiology in Hearing Disorders.

Authors:  Dennis R Trune; Anh Nguyen-Huynh
Journal:  Semin Hear       Date:  2012-08

Review 3.  Physiopathology of the cochlear microcirculation.

Authors:  Xiaorui Shi
Journal:  Hear Res       Date:  2011-08-23       Impact factor: 3.208

Review 4.  Function of the audiovestibular system in children with systemic lupus erythematosus.

Authors:  Ghada Ibrahim Gad; Hanan Abdelateef
Journal:  Curr Allergy Asthma Rep       Date:  2014-07       Impact factor: 4.806

5.  Blocking the glucocorticoid receptor with RU-486 does not prevent glucocorticoid control of autoimmune mouse hearing loss.

Authors:  Dennis R Trune; J Beth Kempton
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

Review 6.  Idiopathic sensorineural hearing disorders in adults--a pragmatic approach.

Authors:  David L George; Sagun Pradhan
Journal:  Nat Rev Rheumatol       Date:  2009-08-04       Impact factor: 20.543

Review 7.  Pathophysiology of the cochlear intrastrial fluid-blood barrier (review).

Authors:  Xiaorui Shi
Journal:  Hear Res       Date:  2016-01-20       Impact factor: 3.208

8.  Strial microvascular pathology and age-associated endocochlear potential decline in NOD congenic mice.

Authors:  Kevin K Ohlemiller; Mary E Rybak Rice; Patricia M Gagnon
Journal:  Hear Res       Date:  2008-08-12       Impact factor: 3.208

9.  Possible association between thyroid autoimmunity and Menière's disease.

Authors:  B Fattori; A Nacci; A Dardano; I Dallan; M Grosso; C Traino; V Mancini; F Ursino; F Monzani
Journal:  Clin Exp Immunol       Date:  2008-01-28       Impact factor: 4.330

Review 10.  Bilateral sudden sensorineural hearing loss as a presenting feature of systemic lupus erythematosus: Case report and brief review of other published cases.

Authors:  Sylvain Chawki; Jessie Aouizerate; Selim Trad; Jacques Prinseau; Thomas Hanslik
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.